Publicaciones en las que colabora con Mercedes Muros de Fuentes (24)

2017

  1. Anti-inflammatory profile of paricalcitol in kidney transplant recipients

    Nefrologia, Vol. 37, Núm. 6, pp. 622-629

2016

  1. Effect of Paricalcitol on FGF-23 and Klotho in Kidney Transplant Recipients

    Transplantation, Vol. 100, Núm. 11, pp. 2432-2438

2015

  1. Inflammatory cytokines in diabetic nephropathy

    Journal of Diabetes Research, Vol. 2015

2014

  1. Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease

    Current Drug Targets, Vol. 15, Núm. 7, pp. 703-709

  2. Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease

    Mediators of Inflammation, Vol. 2014

  3. Tunneled catheters with taurolidine-citrate-heparin lock solution significantly improve the inflammatory profile of hemodialysis patients

    Antimicrobial Agents and Chemotherapy, Vol. 58, Núm. 7, pp. 4180-4184

2013

  1. El sistema del factor de crecimiento fibroblástico 23/Klotho en el contexto del daño cardiovascular

    Medicina Clinica, Vol. 140, Núm. 9, pp. 420-423

  2. Lanthanum carbonate modulates inflammatory profile in hemodialysis patients: Relationship with fibroblast growth factor-23

    European Journal of Inflammation, Vol. 11, Núm. 1, pp. 75-86

  3. Relationship between inflammation and microalbuminuria in prehypertension

    Journal of Human Hypertension, Vol. 27, Núm. 2, pp. 119-125

2012

  1. FGF23/Klotho axis: Phosphorus, mineral metabolism and beyond

    Cytokine and Growth Factor Reviews

2011

  1. Pentoxifylline for Renoprotection in Diabetic Nephropathy: The PREDIAN study. Rationale and basal results

    Journal of Diabetes and its Complications, Vol. 25, Núm. 5, pp. 314-319

2010

  1. New pathogenic perspectives in diabetic renal disease: Diabetic nephropathy as an inflammatory condition

    Nephrology - Dialysis - Transplantation (Nova Science Publishers, Inc.), pp. 1-32

  2. Serum and gene expression profile of tumor necrosis factor-α and interleukin-6 in hypertensive diabetic patients: Effect of amlodipine administration

    International Journal of Immunopathology and Pharmacology, Vol. 23, Núm. 1, pp. 51-59

2009

  1. Mineral metabolism and inflammation in chronic kidney disease patients: A cross-sectional study

    Clinical Journal of the American Society of Nephrology, Vol. 4, Núm. 10, pp. 1646-1654

  2. New pathogenic perspectives in diabetic renal disease: Diabetic nephropathy as an inflammatory condition

    Nephrology - Dialysis - Transplantation (Nova Science Publishers, Inc.), pp. 1-32

  3. Pathogenic perspectives for the role of inflammation in diabetic nephropathy

    Clinical Science, Vol. 116, Núm. 6, pp. 479-492

  4. Tumor necrosis factor-α as a therapeutic target for diabetic nephropathy

    Cytokine and Growth Factor Reviews, Vol. 20, Núm. 2, pp. 165-173

2008

  1. Association of tumor necrosis factor-α with early target organ damage in newly diagnosed patients with essential hypertension

    Journal of Hypertension, Vol. 26, Núm. 11, pp. 2168-2175

  2. Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-α and interleukin-6 in type 2 diabetic patients

    Nephrology Dialysis Transplantation, Vol. 23, Núm. 3, pp. 919-926

2007

  1. Características de los paciente diabéticos referidos por primera vez a las consultas de atención especializada de nefrología

    Nefrologia, Vol. 27, Núm. 2, pp. 154-161